Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of HRS-5346 Formulations in Healthy Participants
NCT07752069Phase 1Not yet recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of MK-7262 in lipoprotein disorder (2 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration at 1 month, Area Under the Concentration-Time Curve From Time Zero to Time t at 1 month and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
MK-7262
03
Conditions
lipoprotein disorder
Beyond the preview
Go deeper on NCT07752069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07752069.